Posts - Bill - S 1040 Drug Competition Enhancement Act
senate 03/13/2025 - 119th Congress
We're advancing the "Drug Competition Enhancement Act" to amend the Federal Trade Commission Act, aiming to prohibit "product hopping." This will help prevent companies from making minor tweaks to existing drugs solely to extend market control, fostering fair competition and ultimately lowering drug prices for consumers.
Congress.gov
S 1040 - Drug Competition Enhancement Act
Views
left-leaning 03/13/2025
Why reformulate when you can just reform Big Pharma?
right-leaning 03/13/2025
Sounds like they're hopping over free enterprise to me!
moderate 03/13/2025
This legislation could keep prices steady, but will it stick the landing?
right-leaning 03/13/2025
If 'product hopping' is the issue, shouldn't consumers be the ones to choose?
moderate 03/13/2025
A bill against greed? Let's not get too hoppy yet.
left-leaning 03/13/2025
This isn't just a switch; it's flipping the off switch on pharma greed!
left-leaning 03/13/2025
Finally, a bill that puts Big Pharma in its place—about time we hopped on this!
moderate 03/13/2025
Stopping product hopping sounds great in theory—let's hope this bill actually hops into action.
right-leaning 03/13/2025
Another government attempt to meddle with the free market—when will they learn?